Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Study of NNC0487-0111 Weekly Injection for Weight Loss in Japanese Adults With Overweight or Obesity
Researchers are evaluating a new medicine called NNC0487-0111 to see if it is safe and effective for helping adults in Japan with excess body weight, including those with overweight or obesity. This Phase 3 clinical study compares NNC0487-0111 with a placebo, a treatment that does not contain active medicine, to understand its effects. The study includes participants with and without type 2 diabetes or knee osteoarthritis, following specific criteria for these groups. Participants receive either NNC0487-0111 or a placebo, both given as weekly injections under the skin using pre-filled pen injectors on the thigh, abdomen, or upper arm. The treatment is combined with a reduced-calorie diet and increased physical activity. Participants receive one of four dose levels of NNC0487-0111 or a matching placebo. The study treatment continues once weekly for up to 84 weeks. During the study, participants are regularly monitored through visits where body weight and waist circumference are measured. The main outcome is the relative change in body weight from the start of the study to week 84. Secondary outcomes include changes in waist size. Safety and adherence are also monitored throughout the study period, which lasts approximately 84 weeks from baseline to the final assessment.
Actively Recruiting
This research investigates response-guided therapy after neoadjuvant endocrine treatment to improve adjuvant care in premenopausal women with hormone receptor-positive, HER2-negative breast cancer. It focuses on optimizing treatment by identifying patients who may safely avoid chemotherapy based on their response to endocrine therapy. The study is a multicenter, randomized phase III trial aiming to compare this approach to standard surgery followed by adjuvant therapy. Participants are randomly assigned to one of two groups one group undergoes upfront breast surgery followed by adjuvant systemic therapy based on pathological findings, and the other group receives neoadjuvant endocrine therapy with an aromatase inhibitor and ovarian function suppression for three months before surgery. Adjuvant treatments vary depending on the patients Oncotype DX recurrence score and endocrine therapy response, with options including endocrine therapy alone, chemotherapy combined with endocrine therapy, or tamoxifen. During the study, participants are monitored for outcomes such as event-free survival, overall survival, relapse-free survival, and distant recurrence-free survival over up to 12 years. Researchers also assess quality of life, safety, and the rate of endocrine therapy use without chemotherapy. The study involves long-term follow-up to evaluate the effectiveness of response-guided therapy in improving treatment decisions for premenopausal women with this breast cancer subtype.